BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
BriaCell Therapeutics Corp. - Common Shares (BCTX)
Company Research
Source: GlobeNewswire
9 of 25 BriaCell patients treated since 2022 remain alive 18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in 9 cases as of their last assessment. Table 1: Ongoing Long-Term SurvivorsPatient/SubtypeMonths Since Study StartAgeNumber of Prior RegimensCycles of Bria-IMT 01-009/ER+/PR+/HER2low47
Show less
Read more
Impact Snapshot
Event Time:
BCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCTX alerts
High impacting BriaCell Therapeutics Corp. - Common Shares news events
Weekly update
A roundup of the hottest topics
BCTX
News
- BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation [Yahoo! Finance]Yahoo! Finance
- BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune ActivationGlobeNewswire
- BriaCell Therapeutics Announces Closing of US$30 million Public OfferingGlobeNewswire
- BrianCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit [Seeking Alpha]Seeking Alpha
- BriaCell Therapeutics Announces Pricing of $30 million Public OfferingGlobeNewswire
BCTX
Sec Filings
- 1/23/26 - Form SCHEDULE
- 1/15/26 - Form 8-K
- 1/14/26 - Form 424B4
- BCTX's page on the SEC website